Clinical Trial: Study of Aspirin in Patients With Vestibular Schwannoma

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas

Brief Summary: This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.

Detailed Summary:
Sponsor: Massachusetts Eye and Ear Infirmary

Current Primary Outcome: Progression Free Survival [ Time Frame: Progression, or around 3.5 years ]

Progression Free Survival (PFS) is the length of time from start of study treatment to tumor growth of more than 20%.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Massachusetts Eye and Ear Infirmary

Dates:
Date Received: March 6, 2017
Date Started: June 2017
Date Completion: February 2022
Last Updated: May 4, 2017
Last Verified: May 2017